Tomomi Kaneda
Research Subjects
Research Interests
Tomomi Kaneda has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akiko Ishida
Pharma Foods International Co., Ltd., Kyoto 615-8245, Japan
1 shared publication - Hiroki Takeo
Medical Corporation Diastep TAKEO Clinic, 4-22-7 Taishido, Setagaya-ku, Tokyo 154-0004, Japan
1 shared publication - Masao Matsuoka
M&I Science CORP, 1-17-26 Nakatsu, Kita-ku, Osaka-shi 531-0073, Japan
1 shared publication - Mio Ono
Research and Development Division, Mitsubishi Corporation Life Sciences Limited, 1-1-3 Yurakucho, Chiyoda-ku, Tokyo 100-0006, Japan
1 shared publication - Takanobu Sakurai
Research and Development Division, Mitsubishi Corporation Life Sciences Limited, Tokyo, Japan
1 shared publication - Utano Nakamura
Pharma Foods International Co., Ltd., 1-49 Goryo-Ohara, Nishikyo-ku, Kyoto 615-8245, Japan
1 shared publication
Latest Publications
- Open Access
The Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial
Glutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and γ-glutamylcysteine (γ-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and γ-glutamylcysteine (γ-Glu-Cys) as cysteine peptide and performed a randomized, double-blind, placebo-controlled study to investigate the effects of orally administered cysteine peptide on human skin brightness using a CM-26d portable spectrophotometer in healthy males and females aged between 20 and 65 years old. Eligible participants were randomly allocated into three groups (cysteine peptide 45 mg: n = 16, 90 mg: n = 15, and placebo: n = 16). Each subject ingested six tablets every day for 12 weeks, and skin brightness was measured at 0, 4, 8, and 12 weeks. As a result, the 45 mg group exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12 (p = 0.028). Moreover, no serious adverse events and changes related to 270 mg study food were observed in the safety trial. Here, we suggest that cysteine peptide is a promising and safe compound for human skin brightness.
Open AccessThe Effect of Cysteine Peptide Ingestion on Skin Brightness, a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Human Clinical Trial
Glutathione (GSH) is present in almost all human cells and has a beneficial effect on human skin brightness. Cysteinylglycine (Cys-Gly) and γ-glutamylcysteine (γ-Glu-Cys) are GSH synthesis components. In this study, we defined glutathione (GSH), cysteinylglycine (Cys-Gly), and γ-glutamylcysteine (γ-Glu-Cys) as cysteine peptide and performed a randomized, double-blind, placebo-controlled study to investigate the effects of orally administered cysteine peptide on human skin brightness using a CM-26d portable spectrophotometer in healthy males and females aged between 20 and 65 years old. Eligible participants were randomly allocated into three groups (cysteine peptide 45 mg: n = 16, 90 mg: n = 15, and placebo: n = 16). Each subject ingested six tablets every day for 12 weeks, and skin brightness was measured at 0, 4, 8, and 12 weeks. As a result, the 45 mg group exhibited arm brightening in a time-dependent manner, and a significant difference was observed compared to the placebo at week 12 (p = 0.028). Moreover, no serious adverse events and changes related to 270 mg study food were observed in the safety trial. Here, we suggest that cysteine peptide is a promising and safe compound for human skin brightness.